Navigation Links
Palliation is rarely a topic in studies on advanced cancer
Date:4/24/2014

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by the German Institute for Quality and Efficiency in Health Care (IQWiG), which has now been published as final report.

Together with external experts, IQWiG analysed studies on four solid tumours as examples: glioblastoma, lung cancer, malignant melanoma, and pancreatic cancer. For this purpose, the research team evaluated publications on RCTs investigating the use of disease-modifying treatments such as chemotherapy or radiation therapy. Studies on purely symptomatic interventions (e.g. colostomies) were not included.

Only 40% of studies name superior treatment goals

The research team included a total of 100 study publications; 25 for each of the four indications. Even though the median survival time for these four types of tumours is usually 24 months at most, in the introductory description of the study setting, only 71% of the publications provided clear information on the advanced phase of disease.

A superior patient-relevant treatment goal was only named in about 40% of the publications. This does not refer to the study outcomes, but to what was clinically intended with the respective intervention and what patients could hope for. Most cases (30 out of 38) referred solely to an increase in life expectancy; two referred solely to quality of life or symptom control.

PROs are clearly underrepresented

Accordingly, the primary outcome recorded in the studies was almost exclusively overall survival or a surrogate parameter such as progression-free survival or tumour response.

Patient-reported outcomes (PROs), which also include quality of life, were not investigated as the primary outcome in any study. They were merely named as secondary or tertiary study outcomes, and only in 36, that is about a third, of the publications. In 31 cases results for PROs were reported in the primary publication. In the remaining five, these findings were presumably provided only in later publications, and thus generally in less prominent journals.

Weighing of benefit and harms not always comprehensible

In most publications authors addressed the benefit-harm ratio of the respective interventions. But the importance of side effects for patients was appropriately reflected and presented only in 22 out of 88 of these publications, and instead played down by certain formulations in 53. All authors drew a corresponding conclusion, but this was comprehensible on the basis of the study results reported beforehand for only 48 of the publications.

Terms are used differently

The report also aimed to clarify terms within the context of "curation" and "palliation". However, this was not possible as these were used inconsistently in the publications analysed and rarely defined.

For instance, the meaning of "salvage therapy" is unclear. "To salvage" means "to rescue", which could lead patients to assume that the treatment they are undergoing will "rescue", that is "cure" them. However, precisely this case is no longer realistic in the specific treatment situation.

Specific treatment situation not adequately represented

Stefan Lange, Deputy Head of IQWiG and one of the authors of the report, sums up: "Our investigation showed that the specific treatment situation of patients in whom the end of life is foreseeable is inadequately represented in publications.

And this deficit is serious, as physicians also refer to the results of clinical studies in their conversations with patients. Both can only conjointly make good decisions about treatment options if they receive complete and unbiased information on the expected benefit and harm.

This is particularly important in diseases that are expected to lead to death in the foreseeable future, especially as therapy usually places a burden on patients. Many of those involved, physicians, researchers and also industry representatives, repeatedly emphasize that quality of life is of paramount importance for this patient group. It is thus all the more incomprehensible that this aspect is still clearly neglected in studies."

Process of report production

The present final report was generated in collaboration with external experts within the framework of the general commission. To promote the Institute's scientific independence, the Federal Joint Committee (G-BA) awarded a general commission to IQWIG in December 2004 and extended it in 2006 to cover information on the quality and efficiency in the health care system. This allows IQWiG to independently select and work on topics. In contrast to other types of reports, no commenting procedure is held for these reports.

The executive summary provides an overview of the background, methods and further results of the report.


'/>"/>

Contact: Dr. Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Despite clear benefits, heart failure clinics are rarely utilized
2. Hospital-acquired UTIs rarely reported in data used to implement penalties
3. Childrens headaches rarely indicate a need for eyeglasses
4. Kids Headaches Rarely Due to Vision Problems, Study Finds
5. Sex between monogamous heterosexuals rarely source of hepatitis C infection
6. Physician-Assisted Suicide Program Rarely Used, Study Finds
7. Potentially life-saving cooling treatment rarely used for in-hospital cardiac arrests
8. Children referred for chest pain rarely have cardiac disease
9. Linked to Liver Failure, Diet Supplement OxyElite Pro Recalled; Parker Waichman LLP Commends FDA for Invoking Rarely Used Enforcement Power in Letter to Supplements Maker
10. Hormone may help predict tubal ectopic pregnancy
11. Gene Signal presents data at ARVO 2012 showing topical aganirsen is active in retinal disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
Breaking Medicine Technology: